Comment

Comment by Maria De Wind on April 15, 2013 at 6:39am

Removal of cannabis from Schedule I of the Controlled Substances Act

Since 1972, there have been numerous proposals in the United States to remove cannabis from Schedule I of the Controlled Substances Act, the most tightly restricted category reserved for drugs which have "no currently accepted medical use".

Comment by Ragnarok on April 15, 2013 at 6:33am

That people can patent nature seems so far out to me.

Comment by Maria De Wind on April 15, 2013 at 12:06am

United States Patent & Trademark Office

Comment by Maria De Wind on April 14, 2013 at 11:56pm

Phytocannabinoids in the treatment of cancer

http://www.google.com/patents/US20130059018

They have patented a NEW INVENTION!

Phytocannabinoids in the treatment of cancer
US 20130059018 A1
Abstract

This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Description

This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS), as a prophylactic or in the treatment of cancer. Typically the cancer to be treated is a cancer of the: prostate, breast, skin, glioma, colon, lung or a bone or lymph metastasis. The phytocannabinoids may be used in combination with other cancer treatments.

Claims

1. A method of treating a patient comprising administering a therapeutically effective amount of a cannabis plant extract comprising a phytocannabinoid containing component and a non-phytocannabinoid containing component, wherein the phytocannabinoid containing component comprises at least 50% (w/w) of the cannabis plant extract and in which the principle is not tetrahydrocannabinol (THC) or cannabidiol (CBD), and the non-phytocannabinoid containing component comprises at least 15% (w/w) of the cannabis plant extract and further comprises a monoterpene fraction comprising a principle monoterpene which is selected from myrcenes or pinenes and a sesquiterpene fraction comprising a principle sesquiterpene which is selected from caryophyllenes or humulenes to the patient.

...And there is more, much more reading on the link provided.

• ‹ Previous
• 1
• 2
• Next ›
• Page